TGFB1 and neoplasm: Preclinical studies in the LKR-13 adenocarcinoma model identified TGFβ as a suppressor of anti-tumor TAN function, and an antibody blockade of TGFβ resulted in a significant expansion of anti-tumor TANs indispensable for subsequent anti-tumor immune responses [122].